Mesoblast Limited (MSB.XA)
- Previous Close
0.9050 - Open
0.9200 - Bid --
- Ask 0.9350 x --
- Day's Range
0.8950 - 0.9500 - 52 Week Range
0.2550 - 1.4300 - Volume
2,254,102 - Avg. Volume
3,487,920 - Market Cap (intraday)
-- - Beta (5Y Monthly) 2.59
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2040 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
www.mesoblast.com83
Full Time Employees
June 30
Fiscal Year Ends
--
Sector
--
Industry
Recent News: MSB.XA
Performance Overview: MSB.XA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MSB.XA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MSB.XA
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-5.61%
Return on Equity (ttm)
-14.49%
Revenue (ttm)
7.47M
Net Income Avi to Common (ttm)
-73.06M
Diluted EPS (ttm)
-0.2040
Balance Sheet and Cash Flow
Total Cash (mrq)
77.55M
Total Debt/Equity (mrq)
23.98%
Levered Free Cash Flow (ttm)
-63.95M
Company Insights: MSB.XA
MSB.XA does not have Company Insights